CML Patients With Prior Malignancies Have Excellent Outcomes
Patients with chronic myeloid leukemia with a history of prior malignancies generally fare as well as those without such a history, according to a new study.
Cost of TKIs May Be Deterrant in CML Patients on Medicare
An analysis of tyrosine kinase inhibitor initiation and adherence in Medicare beneficiaries with chronic myeloid leukemia suggests that out-of-pocket costs may be a barrier to treatment.
Long-Term Follow-Up Shows Imatinib Discontinuation Remains Safe
The STIM1 study shows that patients with chronic myeloid leukemia who have undetectable minimal residual disease can safely discontinue imatinib therapy.
EZH2 May Be Required for CML Initiation, Could Represent Therapeutic Target
A study found that the protein EZH2 is required for chronic myeloid leukemia initiating cells to survive. Inhibiting EZH2 could improve outcomes in TKI-resistant disease.
EUTOS Registry Shows Good CML Outcomes Outside Trials
Data from the large, population-based EUTOS registry showed strong survival outcomes in patients with CML, and validated risk scores as prognostic of outcome.
Nilotinib, Dasatinib Offer Similar Outcomes in CML Patients
A propensity score–matched comparison of two phase II trials found that dasatinib and nilotinib offer similar responses and outcomes as first-line therapy for patients with chronic-phase CML.
ABCB1 mRNA Could Predict TKI Response in CML
Early evaluation of ABCB1 mRNA expression may help identify CML patients who are likely to be resistant to first- and second-generation tyrosine kinase inhibitors.
By clicking Accept, you agree to become a member of the UBM Medica Community.